Propanc’s PRP Shows Potential to Reverse Chemotherapy Resistance in Pancreatic Cancer

  • Propanc Biopharma’s lead asset PRP demonstrated the ability to reprogram chemotherapy-resistant pancreatic cancer cells in preclinical research led by Dr. Maria Belén Toledo.
  • PRP pre-treatment followed by chemotherapy showed the strongest functional response, reducing cancer cell proliferation by 50-54% and long-term clonogenic survival by 39-59%.
  • The Phase 1b First-In-Human study for advanced cancer patients with solid tumors is planned for Q1 2027.
  • PRP induced coordinated changes across multiple biological processes associated with chemoresistance, tumor cell plasticity, and aggressive behavior.

Propanc Biopharma’s findings position PRP as a potential game-changer in addressing chemotherapy resistance, a critical challenge in cancer treatment. The company’s focus on reprogramming resistant tumor cells aligns with broader industry trends toward precision medicine and combination therapies. The upcoming Phase 1b study will be a key milestone in determining PRP’s therapeutic potential and market positioning.

Clinical Translation
Whether PRP’s preclinical success in reprogramming chemotherapy-resistant cells will translate into clinical benefits for patients.
Combination Strategies
The pace at which Propanc can develop and validate sequential combinatorial approaches involving PRP and other therapies.
Regulatory Pathway
How the Phase 1b study results will shape the regulatory strategy for PRP’s approval and commercialization.